Media headlines about AzurRx BioPharma (NASDAQ:AZRX) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AzurRx BioPharma earned a news impact score of 0.09 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.6676895483983 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
Separately, HC Wainwright set a $8.00 price objective on AzurRx BioPharma and gave the stock a “buy” rating in a report on Wednesday, August 16th.
Shares of AzurRx BioPharma (NASDAQ:AZRX) traded down $0.10 during trading hours on Tuesday, hitting $3.24. The stock had a trading volume of 7,300 shares, compared to its average volume of 32,866. AzurRx BioPharma has a one year low of $2.40 and a one year high of $5.25.
WARNING: This article was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/05/azurrx-biopharma-azrx-earns-daily-news-impact-rating-of-0-09.html.
AzurRx BioPharma Company Profile
AzurRx BioPharma, Inc is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101.
Receive News & Ratings for AzurRx BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.